Table 1.

Demographic data and CSF results by diagnostic group

Groups and subgroupsSubjects, n (M/F)Age, y, median (range)MMSENo. cases by number of APOE e4 alleles, n (0/1/2 alleles)Tau, pg/mL, median (p25-p75)42 (pg/mL), median (p25-p75)Correctly classified using tau-Aβ42 function, n (%)
* Group AD consists of patients with probable AD (n = 146), possible AD (n = 2), or mixed vascular/AD dementia (n = 2).
† Neurologic control subjects include those without dementia with compression mononeuropathy (n = 37), Bell’s palsy (n = 5), neurosis (n = 5), tension headache (n = 4), depression without dementia (n = 3), carpal tunnel syndrome (n = 2) and myalgia (n = 2).
‡ Vascular dementia includes Binswanger disease (n = 2) and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (n = 1).
§ The subgroup neurodegeneration with dementia includes Parkinson’s dementia (n = 7), supranuclear palsy (n = 2), corticobasal degeneration (n = 2), dementia with Lewy bodies (n = 1), subcortical dementia (n = 1), primary progressive aphasia (n = 1), and leukoencephalopathy (n = 1).
∥ The subgroup inflammatory neurologic disorders included MS (n = 20), optic neuritis (n = 5), Guillain-Barré syndrome (n = 9), subacute sclerosing panencephalitis (n = 2), or other inflammatory neurologic disorders (n = 4).
¶ The subgroup degenerative neurologic disorders without dementia includes ALS (n = 3), olivopontocerebellar degeneration (n = 4), and PD (n = 1).
** The subgroup other neurologic disorders includes epilepsia (n = 8), polyneuropathy (n = 9), depression associated with cognitive changes (n = 3), benign intracranial hypertension (n = 2), myopathy (n = 2), oculomotor palsy (n = 1), Parsonage-Turner syndrome (n = 1), and other unspecified neurologic conditions without dementia (n = 10).
†† The group vascular events and tumors includes stroke (n = 8), vascular myelopathy (n = 1), vasculitis (n = 1), subarachnoidal bleeding (n = 1), primary brain tumor (n = 2), brain metastasis (n = 1), and postanoxia vegetative status (n = 1).
‡‡ The group infections includes meningitis (n = 13), HIV infection (n = 2), myelitis (n = 2), encephalitis (n = 1), cerebellitis (n = 1), syphilis (n = 1), and neuroborreliosis (n = 1).
MMSE = Mini-Mental State Examination; NA = no data available.
n(p25-p-75)LineTree
AD (group AD)*150 (42/108)74 (42–90)12719 (13–22)84 (30/44/10)425 (274–713)487 (394–622)127 (85)122 (81)
AD (Center 2)58 (14/44)76 (53–86)5720 (16–23)35 (9/21/5)464 (375–761)571 (458–682)50 (86)47 (81)
AD (others)92 (28/64)72 (42–90)7018 (11–21)49 (21/23/5)366 (241–677)428 (335–560)77 (84)75 (82)
Mild memory impairment4 (3/1)73 (63–79)430 (29–30)1 (1/0/0)710 (531–854)494 (356–631)NANA
All control subjects (group CON)100 (25/75)68 (17–87)6129 (28–30)11 (10/0/1)195 (121–294)849 (682–1063)87 (87)92 (92)
Healthy control subjects (Center 2)42 (3/39)74 (60–85)4229 (28–29)NA219 (134–318)1001 (797–1214)39 (93)41 (98)
Neurologic control subjects (other centers)58 (22/36)57 (17–87)1930 (30–30)11 (10/0/1)167 (107–290)769 (608–913)48 (83)51 (88)
Non-AD dementia (group NAD)79 (45/34)74 (39–94)6421 (15–26)23 (12/5/6)220 (122–426)603 (430–744)46 (58)38 (48)
Vascular dementia33 (21/12)73 (39–91)3021 (14–26)17 (7/5/5)230 (133–451)597 (425–739)18 (55)15 (45)
Frontotemporal dementia11 (7/4)75 (46–94)1120 (15–23)5 (5/0/0)209 (182–468)640 (599–821)6 (55)6 (55)
Normal pressure hydrocephalus20 (11/9)74 (51–91)2023 (16–29)NA154 (86–291)505 (417–732)14 (70)10 (50)
Neurodegeneration with dementia§15 (6/9)72 (43–79)318 (10–22)1 (0/0/1)249 (113–438)619 (461–726)8 (53)7 (47)
Neurologic disorders (group ND)84 (38/46)49 (16–84)NA7 (6/1/0)160 (125–217)643 (522–786)72 (86)73 (87)
Inflammatory neurologic disorders40 (21/19)41 (16–74)NA1 (0/1/0)145 (105–175)652 (544–797)38 (95)37 (93)
Neurodegeneration without dementia8 (3/5)65 (55–80)NANA189 (157–205)597 (535–711)7 (88)7 (88)
Other neurologic disorders**36 (14/22)54 (19–84)NA6 (6/0/0)194 (139–269)642 (501–847)27 (75)29 (81)
Vascular events and tumors††15 (6/9)56 (35–79)NA2 (2/0/0)329 (249–513)674 (536–742)8 (53)8 (53)
Infections‡‡21 (15/6)32 (4–78)NANA170 (88–363)574 (378–761)11 (52)10 (48)